Skip to main content
Top
Published in: European Journal of Nuclear Medicine and Molecular Imaging 7/2014

01-07-2014 | Original Article

Amyloid PET imaging in Alzheimer’s disease: a comparison of three radiotracers

Authors: S. M. Landau, B. A. Thomas, L. Thurfjell, M. Schmidt, R. Margolin, M. Mintun, M. Pontecorvo, S. L. Baker, W. J. Jagust, the Alzheimer’s Disease Neuroimaging Initiative

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 7/2014

Login to get access

Abstract

Purpose

The increasing use of amyloid PET in Alzheimer’s disease research and clinical trials has motivated efforts to standardize methodology. We compared retention of the 11C radiotracer Pittsburgh Compound B (PiB) and that of two 18F amyloid radiotracers (florbetapir and flutemetamol) using two study populations. We also examined the feasibility of converting between tracer-specific measures, using PiB as the common link between the two 18F tracers.

Methods

One group of 40 subjects underwent PiB and flutemetamol imaging sessions and a separate group of 32 subjects underwent PiB and florbetapir imaging sessions. We compared cortical and white matter retention for each 18F tracer relative to that of PiB, as well as retention in several reference regions and image analysis methods. Correlations between tracer pairs were used to convert tracer-specific threshold values for amyloid positivity between tracers.

Results

Cortical retention for each pair of tracers was strongly correlated regardless of reference region (PiB–flutemetamol, ρ = 0.84–0.99; PiB–florbetapir, ρ = 0.83–0.97) and analysis method (ρ = 0.90–0.99). Compared to PiB, flutemetamol had higher white matter retention, while florbetapir had lower cortical retention. Two previously established independent thresholds for amyloid positivity were highly consistent when values were converted between tracer pairs.

Conclusion

Despite differing white and grey matter retention characteristics, cortical retention for each 18F tracer was highly correlated with that of PiB, enabling conversion of thresholds across tracer measurement scales with a high level of internal consistency. Standardization of analysis methods and measurement scales may facilitate the comparison of amyloid PET data obtained using different tracers.
Appendix
Available only for authorised users
Literature
1.
2.
go back to reference Vandenberghe R, Van Laere K, Ivanoiu A, Salmon E, Bastin C, Triau E, et al. 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. Ann Neurol. 2010;68(3):319–29. doi:10.1002/ana.22068.PubMedCrossRef Vandenberghe R, Van Laere K, Ivanoiu A, Salmon E, Bastin C, Triau E, et al. 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. Ann Neurol. 2010;68(3):319–29. doi:10.​1002/​ana.​22068.PubMedCrossRef
3.
go back to reference Villemagne VL, Mulligan RS, Pejoska S, Ong K, Jones G, O'Keefe G, et al. Comparison of 11C-PiB and 18F-florbetaben for Abeta imaging in ageing and Alzheimer's disease. Eur J Nucl Med Mol Imaging. 2012;39(6):983–9. doi:10.1007/s00259-012-2088-x.PubMedCrossRef Villemagne VL, Mulligan RS, Pejoska S, Ong K, Jones G, O'Keefe G, et al. Comparison of 11C-PiB and 18F-florbetaben for Abeta imaging in ageing and Alzheimer's disease. Eur J Nucl Med Mol Imaging. 2012;39(6):983–9. doi:10.​1007/​s00259-012-2088-x.PubMedCrossRef
4.
go back to reference Wolk DA, Zhang Z, Boudhar S, Clark CM, Pontecorvo MJ, Arnold SE. Amyloid imaging in Alzheimer's disease: comparison of florbetapir and Pittsburgh compound-B positron emission tomography. J Neurol Neurosurg Psychiatry. 2012;83(9):923–6. doi:10.1136/jnnp-2012-302548.PubMedCrossRef Wolk DA, Zhang Z, Boudhar S, Clark CM, Pontecorvo MJ, Arnold SE. Amyloid imaging in Alzheimer's disease: comparison of florbetapir and Pittsburgh compound-B positron emission tomography. J Neurol Neurosurg Psychiatry. 2012;83(9):923–6. doi:10.​1136/​jnnp-2012-302548.PubMedCrossRef
11.
go back to reference Nelissen N, Van Laere K, Thurfjell L, Owenius R, Vandenbulcke M, Koole M, et al. Phase 1 study of the Pittsburgh compound B derivative 18F-flutemetamol in healthy volunteers and patients with probable Alzheimer disease. J Nucl Med. 2009;50(8):1251–9. doi:10.2967/jnumed.109.063305.PubMedCrossRef Nelissen N, Van Laere K, Thurfjell L, Owenius R, Vandenbulcke M, Koole M, et al. Phase 1 study of the Pittsburgh compound B derivative 18F-flutemetamol in healthy volunteers and patients with probable Alzheimer disease. J Nucl Med. 2009;50(8):1251–9. doi:10.​2967/​jnumed.​109.​063305.PubMedCrossRef
12.
go back to reference Thomas BA, Erlandsson K, Modat M, Thurfjell L, Vandenberghe R, Ourselin S, et al. The importance of appropriate partial volume correction for PET quantification in Alzheimer's disease. Eur J Nucl Med Mol Imaging. 2011;38(6):1104–19. doi:10.1007/s00259-011-1745-9.PubMedCrossRef Thomas BA, Erlandsson K, Modat M, Thurfjell L, Vandenberghe R, Ourselin S, et al. The importance of appropriate partial volume correction for PET quantification in Alzheimer's disease. Eur J Nucl Med Mol Imaging. 2011;38(6):1104–19. doi:10.​1007/​s00259-011-1745-9.PubMedCrossRef
13.
16.
go back to reference Lundqvist R, Lilja J, Thomas BA, Lotjonen J, Villemagne VL, Rowe CC, et al. Implementation and validation of an adaptive template registration method for 18F-flutemetamol imaging data. J Nucl Med. 2013;54(8):1472–8. doi:10.2967/jnumed.112.115006.PubMedCrossRef Lundqvist R, Lilja J, Thomas BA, Lotjonen J, Villemagne VL, Rowe CC, et al. Implementation and validation of an adaptive template registration method for 18F-flutemetamol imaging data. J Nucl Med. 2013;54(8):1472–8. doi:10.​2967/​jnumed.​112.​115006.PubMedCrossRef
18.
go back to reference Joshi AD, Pontecorvo MJ, Clark CM, Carpenter AP, Jennings DL, Sadowsky CH, et al. Performance characteristics of amyloid PET with florbetapir F 18 in patients with alzheimer's disease and cognitively normal subjects. J Nucl Med. 2012;53(3):378–84. doi:10.2967/jnumed.111.090340.PubMedCrossRef Joshi AD, Pontecorvo MJ, Clark CM, Carpenter AP, Jennings DL, Sadowsky CH, et al. Performance characteristics of amyloid PET with florbetapir F 18 in patients with alzheimer's disease and cognitively normal subjects. J Nucl Med. 2012;53(3):378–84. doi:10.​2967/​jnumed.​111.​090340.PubMedCrossRef
19.
go back to reference Clark CM, Pontecorvo MJ, Beach TG, Bedell BJ, Coleman RE, Doraiswamy PM, et al. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-beta plaques: a prospective cohort study. Lancet Neurol. 2012;11(8):669–78. doi:10.1016/S1474-4422(12)70142-4.PubMedCrossRef Clark CM, Pontecorvo MJ, Beach TG, Bedell BJ, Coleman RE, Doraiswamy PM, et al. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-beta plaques: a prospective cohort study. Lancet Neurol. 2012;11(8):669–78. doi:10.​1016/​S1474-4422(12)70142-4.PubMedCrossRef
Metadata
Title
Amyloid PET imaging in Alzheimer’s disease: a comparison of three radiotracers
Authors
S. M. Landau
B. A. Thomas
L. Thurfjell
M. Schmidt
R. Margolin
M. Mintun
M. Pontecorvo
S. L. Baker
W. J. Jagust
the Alzheimer’s Disease Neuroimaging Initiative
Publication date
01-07-2014
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 7/2014
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-014-2753-3

Other articles of this Issue 7/2014

European Journal of Nuclear Medicine and Molecular Imaging 7/2014 Go to the issue